This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The molecular test was given to all patients with thyroid nodules and an indeterminate fine-needle aspiration biopsy (FNAB) result. The test used aspirated material, typically collected with two passes of a 25-to 27-gauge needle, to evaluate the messenger ribonucleic acid expression for 142 genes. These data were analysed, using a proprietary algorithm, to class the nodules as either molecularly benign or suspicious. The comparator was conventional cytology.
Location/setting
USA/secondary care.
Methods

Analytical approach:
The analysis was based on a Markov model, with a five-year time horizon. The authors stated that it was carried out from the perspective of society, but limited to the perspective of the US health care system.
Effectiveness data:
Most of the clinical inputs were from a variety of published sources, including literature reviews, government publications, professional society guidelines, and clinical trials. The key data were from published decision analyses on similar questions in thyroid nodule management. Some data were from a panel of six medical and surgical thyroid experts working at the Johns Hopkins Medical Institutions. The sensitivity and specificity of the diagnostic tests were the main inputs.
Monetary benefit and utility valuations:
The utility values for the model states were from published literature or the opinions of the expert panel. The panel used the time trade-off method to estimate the utility weights.
Measure of benefit:
Quality-adjusted life-years (QALYs) were the summary benefit measure and were discounted at an annual rate of 3%.
Cost data:
The economic analysis included the costs of surgery, in-patient care, out-patient care (clinic visits, ultrasound scans, and radioiodine scans), the treatment of complications, and follow-up (additional clinic visits, laboratory tests, imaging procedures, and medications). Most of these costs were from nationally representative sources, such as the Centers for
